Liz Y. Han

6.7k total citations
34 papers, 3.4k citations indexed

About

Liz Y. Han is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Liz Y. Han has authored 34 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 14 papers in Reproductive Medicine and 11 papers in Oncology. Recurrent topics in Liz Y. Han's work include Ovarian cancer diagnosis and treatment (14 papers), Angiogenesis and VEGF in Cancer (12 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Liz Y. Han is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Angiogenesis and VEGF in Cancer (12 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Liz Y. Han collaborates with scholars based in United States, South Korea and Australia. Liz Y. Han's co-authors include Aparna A. Kamat, Anil K. Sood, Charles N. Landen, Yvonne G. Lin, David M. Gershenson, William M. Merritt, Whitney A. Spannuth, Susan K. Lutgendorf, Robert L. Coleman and Premal H. Thaker and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Liz Y. Han

33 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liz Y. Han United States 25 1.7k 1.0k 804 503 387 34 3.4k
David M. Gershenson United States 26 1.8k 1.0× 1.1k 1.1× 870 1.1× 643 1.3× 316 0.8× 31 3.4k
Aparna A. Kamat United States 37 2.4k 1.4× 1.2k 1.2× 1.2k 1.6× 699 1.4× 390 1.0× 62 4.7k
Nicholas B. Jennings United States 27 1.3k 0.8× 718 0.7× 439 0.5× 256 0.5× 478 1.2× 45 2.5k
Lingegowda S. Mangala United States 37 2.5k 1.4× 860 0.8× 1.3k 1.6× 267 0.5× 201 0.5× 73 4.0k
Whitney A. Spannuth United States 25 1.2k 0.7× 741 0.7× 403 0.5× 487 1.0× 100 0.3× 33 2.5k
Gábor Halmos United States 41 1.8k 1.1× 1.8k 1.7× 489 0.6× 399 0.8× 221 0.6× 163 5.0k
Charles N. Landen United States 49 4.5k 2.6× 2.4k 2.3× 1.6k 2.0× 1.3k 2.5× 418 1.1× 114 7.5k
Mauro Bologna Italy 36 1.7k 1.0× 1.1k 1.0× 722 0.9× 57 0.1× 178 0.5× 116 3.5k
Xavier Dolcet Spain 35 2.4k 1.4× 882 0.8× 999 1.2× 376 0.7× 47 0.1× 85 4.2k
Pablo E. Vivas‐Mejía Puerto Rico 27 1.4k 0.8× 454 0.4× 652 0.8× 147 0.3× 116 0.3× 66 2.3k

Countries citing papers authored by Liz Y. Han

Since Specialization
Citations

This map shows the geographic impact of Liz Y. Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liz Y. Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liz Y. Han more than expected).

Fields of papers citing papers by Liz Y. Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liz Y. Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liz Y. Han. The network helps show where Liz Y. Han may publish in the future.

Co-authorship network of co-authors of Liz Y. Han

This figure shows the co-authorship network connecting the top 25 collaborators of Liz Y. Han. A scholar is included among the top collaborators of Liz Y. Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liz Y. Han. Liz Y. Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kamat, Aparna A., Mavis S. Fletcher, Lynn M. Gruman, et al.. (2021). Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer. Clinical Cancer Research. 27(15). 4455–4455.
2.
Powell, C. Bethan, Cecile A. Laurent, Giuseppe Ciaravino, et al.. (2020). Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. Gynecologic Oncology. 159(1). 221–228. 18 indexed citations
3.
Kamat, Aparna A., Mathew Baldwin, Diana L. Urbauer, et al.. (2010). Plasma cell‐free DNA in ovarian cancer. Cancer. 116(8). 1918–1925. 135 indexed citations
4.
Han, Liz Y., Vasilios Karavasilis, Shibani Nicum, et al.. (2010). Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. European Journal of Cancer. 46(8). 1359–1364. 23 indexed citations
5.
Han, Liz Y., Emma Kipps, & Stan B. Kaye. (2010). Current treatment and clinical trials in ovarian cancer. Expert Opinion on Investigational Drugs. 19(4). 521–534. 13 indexed citations
6.
Han, Liz Y., et al.. (2009). Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.. PubMed. 54(4). 259–60. 2 indexed citations
7.
Merritt, William M., Christopher G. Danes, Mian M.K. Shahzad, et al.. (2009). Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biology & Therapy. 8(16). 1596–1603. 35 indexed citations
8.
Lin, Yvonne G., Anand Immaneni, William M. Merritt, et al.. (2008). Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth. Clinical Cancer Research. 14(17). 5437–5446. 51 indexed citations
9.
Spannuth, Whitney A., Alpa M. Nick, Nicholas B. Jennings, et al.. (2008). Functional significance of VEGFR‐2 on ovarian cancer cells. International Journal of Cancer. 124(5). 1045–1053. 124 indexed citations
10.
Merritt, William M., Yvonne G. Lin, Whitney A. Spannuth, et al.. (2008). Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth. JNCI Journal of the National Cancer Institute. 100(5). 359–372. 195 indexed citations
11.
Lü, Chunhua, Tomás Bonome, Yang Li, et al.. (2007). Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma. Cancer Research. 67(4). 1757–1768. 149 indexed citations
12.
Kim, Tae Jin, Murali K. Ravoori, Charles N. Landen, et al.. (2007). Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma. Cancer Research. 67(19). 9337–9345. 78 indexed citations
13.
Kamat, Aparna A., Tae Jin Kim, Charles N. Landen, et al.. (2007). Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer. Cancer Research. 67(1). 281–288. 113 indexed citations
14.
Halder, Jyotsnabaran, Yvonne G. Lin, William M. Merritt, et al.. (2007). Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma. Cancer Research. 67(22). 10976–10983. 181 indexed citations
15.
Landen, Charles N., Yvonne G. Lin, Guillermo N. Armaiz-Peña, et al.. (2007). Neuroendocrine Modulation of Signal Transducer and Activator of Transcription-3 in Ovarian Cancer. Cancer Research. 67(21). 10389–10396. 117 indexed citations
16.
Han, Liz Y., Charles N. Landen, José G. Treviño, et al.. (2006). Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Research. 66(17). 8633–8639. 68 indexed citations
17.
Landen, Charles N., William M. Merritt, Lingegowda S. Mangala, et al.. (2006). Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biology & Therapy. 5(12). 1708–1713. 83 indexed citations
18.
Lin, Yvonne G., Liz Y. Han, Aparna A. Kamat, et al.. (2006). EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 109(2). 332–340. 91 indexed citations
19.
Merritt, William M., Premal H. Thaker, Charles N. Landen, et al.. (2006). Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biology & Therapy. 5(10). 1357–1360. 19 indexed citations
20.
Wu, Xiaohua, Liz Y. Han, Xin Xu, & Ziting Li. (2004). Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation. Gynecologic Oncology. 95(3). 746–749. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David M. Gershenson Breakdown of academic impact, for papers by Aparna A. Kamat Breakdown of academic impact, for papers by Nicholas B. Jennings Breakdown of academic impact, for papers by Lingegowda S. Mangala Breakdown of academic impact, for papers by Whitney A. Spannuth Breakdown of academic impact, for papers by Gábor Halmos Breakdown of academic impact, for papers by Charles N. Landen Breakdown of academic impact, for papers by Mauro Bologna Breakdown of academic impact, for papers by Xavier Dolcet Breakdown of academic impact, for papers by Pablo E. Vivas‐Mejía
Rankless by CCL
2026